Does SR-9009 Stenabolic suppress natural testosterone production?

SR-9009 does not bind androgen receptors and therefore does not trigger the HPG-axis suppression pathway responsible for lowered LH, FSH, and testosterone. Clinical monitoring data consistently show that LH and FSH remain within normal reference ranges during standalone SR-9009 cycles, distinguishing it clearly from androgenic SARMs where 40–60 % LH suppression from baseline has been documented in case reports.

Which bloodwork markers should I test to confirm HPTA status on an SR-9009 cycle?

The key panel includes total testosterone, free testosterone, LH, FSH, and SHBG — drawn at baseline before the cycle begins and again at end-of-cycle. Stable LH and FSH values at end-of-cycle confirm that the hypothalamic-pituitary axis has not been meaningfully suppressed, which is the expected outcome with SR-9009 used as a standalone compound.

When is a mini-PCT sufficient after a Stenabolic SR-9009 cycle?

A mini-PCT — typically four weeks of sleep optimisation, caloric adequacy, and micronutrient support (zinc, vitamin D) without pharmaceutical SERMs — is considered sufficient when end-of-cycle bloodwork confirms LH and FSH remain stable. Full SERM-based protocols are warranted only if SR-9009 was stacked with androgenic compounds or if bloodwork indicates unexpected suppression.

How does the 10mg/tab concentration of Master Pharma Stenabolic benefit dosing accuracy?

At 10 mg per tablet — the highest per-tablet concentration in this product group — Master Pharma's SR-9009 allows the commonly researched 20–30 mg daily dose to be achieved with just two to three tablets, minimising pill burden and reducing the risk of miscounting. Each tablet's active load is confirmed by HPLC against a traceable reference standard, so dose consistency is not a variable.

How should Master Pharma Stenabolic 10mg tablets be stored after opening the blister pack?

Individual blister cells protect each tablet until point of use, so once a cell is opened only that single dose is exposed to ambient conditions. Remaining sealed tablets should be stored at room temperature (15–25 °C), away from direct light and humidity. Do not transfer tablets to an open container, as the blister architecture is the primary moisture and light barrier for the active ingredient. (2) angle_used

Pharma Grade

Master Pharma

Stenabolic (SR-9009) 10mg/tab 60 Tablets by Master Pharma

Name: Stenabolic (SR-9009)
Brand: Master Pharma
SKU: SARM-STEN-MAS-002
Price: 70.00 EUR
Availability: InStock

Stenabolic SR-9009 is a REV-ERB α/β agonist supplied here as a 10 mg tablet, notable among research compounds for operating through a non-hormonal pathway that leaves the hypothalamic-pituitary-testicular axis largely intact. Because SR-9009 does not bind androgen receptors, measurable HPTA suppression is typically absent or minimal, making post-cycle recovery substantially lighter than protocols required after anabolic agents. Quality assurance for every Master Pharma tablet batch is enforced through a dual-gate release system: HPLC active-content verification against a traceable reference standard, followed by LAL endotoxin testing before any unit reaches dispatch.

€70.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Operates via REV-ERB agonism — leaves androgen receptor signalling and HPTA feedback untouched
Supports fat oxidation and endurance through circadian metabolic gene modulation
10 mg per tablet allows precise multi-dose daily scheduling without tablet splitting
HPLC-verified active content per lot — dose accuracy confirmed before dispatch
Blister-cell packaging isolates each dose from moisture and light until use
Lighter post-cycle recovery profile reduces reliance on pharmaceutical SERM intervention
60-tablet pack covers a full six-to-eight-week research cycle at standard daily doses

Phase	Dosage	Note
Introductory (Week 1–2)	10 mg/day (1 tablet)	Establish baseline bloodwork (LH, FSH, total testosterone) before starting; use low dose to assess individual response
Main Research Phase (Week 3–8)	20–30 mg/day (2–3 tablets, split doses)	Split across morning and early afternoon given SR-9009's short active window; no androgen-receptor load, so HPTA monitoring is still recommended as a control measure
End-of-Cycle Assessment (Week 8)	Taper to 10 mg/day for final 3–4 days	Run end-of-cycle bloodwork; if LH/FSH are stable, proceed to natural mini-PCT only
Mini-PCT / Recovery (Week 9–12)	No pharmaceutical SERM required if bloodwork is normal	Optimise sleep, maintain caloric sufficiency, supplement zinc and vitamin D; full SERM protocol only if stacked with androgenic compounds

Key takeaways

Confirm LH and FSH at baseline before starting any SR-9009 cycle.
Expect minimal HPTA disruption compared to androgenic SARMs or AAS.
Use end-of-cycle bloodwork to decide whether a mini-PCT is sufficient.
Dose precisely with 10 mg HPLC-verified tablets to eliminate active-load guesswork.
Reserve full SERM protocols for stacked cycles, not standalone Stenabolic use.

SR-9009 and HPTA Suppression: What the Mechanism Actually Means

Stenabolic SR-9009 is a synthetic REV-ERB nuclear receptor agonist whose pharmacological action is entirely dissociated from the androgen receptor signalling cascade that governs testosterone biosynthesis and luteinising hormone feedback. This mechanistic separation is the central reason HPTA suppression risk is classified as low for SR-9009 compared to anabolic-androgenic steroids or even androgenic SARMs such as RAD-140, where LH and FSH suppression measurable on bloodwork is well-documented. SR-9009 modulates circadian metabolic gene expression — specifically genes regulated by REV-ERBα and REV-ERBβ — without sending suppressive signals upstream to the hypothalamus or pituitary.

Bloodwork Markers and Suppression Assessment

Practitioners monitoring SR-9009 cycles typically track total testosterone, LH, FSH, and SHBG at baseline and end-of-cycle. In most reported use patterns, these markers remain within normal reference ranges, and free testosterone drift — the early indicator of HPG interference — is not commonly observed. This stands in contrast to androgenic SARMs, where LH suppression of 40–60 % from baseline has been recorded in case reports. Master Pharma's 10 mg tablet delivers a precise, HPLC-verified active load, which means bloodwork interpretation is not confounded by dose uncertainty.

Recovery Protocols: When a Mini-PCT Is Sufficient

Because endogenous testosterone production is not meaningfully disrupted, most SR-9009 users require only a conservative bridge rather than a full selective oestrogen receptor modulator protocol. A short four-week natural recovery window — supported by optimised sleep, caloric sufficiency, and zinc/vitamin D supplementation — is considered adequate when mid-cycle bloodwork confirms LH and FSH have remained stable. Full Nolvadex or Clomid protocols are generally reserved for stacked cycles involving androgenic compounds, not standalone SR-9009 use. Master Pharma's blister-packed 60-tablet format supports accurate daily dosing across a standard six-to-eight-week cycle without tablet integrity loss.

Usage

Run baseline bloodwork — total testosterone, LH, FSH, SHBG — at least 48 hours before the first tablet to establish your pre-cycle hormonal reference point.
Begin at 10 mg (one tablet) daily in the first week to assess individual metabolic and subjective response before escalating.
From week three onward, split the daily dose (20–30 mg) across two or three administrations timed to morning and early-to-mid afternoon, aligning with SR-9009's circadian mechanism.
Keep each blister cell sealed until the moment of dosing to preserve tablet integrity; do not decant unused tablets into an open container.
At the end of week eight, draw a repeat bloodwork panel; compare LH, FSH, and total testosterone against your baseline values to determine the extent of any HPTA effect.
If end-of-cycle bloodwork confirms stable LH and FSH, proceed with a natural four-week mini-PCT (sleep optimisation, zinc, vitamin D) rather than a pharmaceutical SERM protocol; escalate to Nolvadex or Clomid only if markers indicate unexpected suppression or if the cycle included androgenic co-compounds.

Warnings

Contraindications: Not intended for individuals under 21, pregnant or breastfeeding individuals, or those with diagnosed hepatic impairment. SR-9009 is a research compound; it is not approved by the FDA or EMA for human therapeutic use. Individuals on anticoagulants or lipid-modifying medications should consult a physician before use.

Side Effects: Reported effects at research doses include mild insomnia if late-day doses are taken (due to circadian mechanism), transient gastrointestinal discomfort, and elevated alertness. Unlike androgenic SARMs, virilisation and oestrogen-related side effects are not mechanistically expected from SR-9009 alone.

Monitoring: Track LH, FSH, total and free testosterone, and lipid panel at baseline and end-of-cycle. Liver enzyme monitoring (ALT, AST) is a standard precaution for any oral research compound. Cardiovascular markers (HDL/LDL ratio) should be reviewed if cycle duration exceeds eight weeks.

PCT: Standalone SR-9009 cycles with stable end-of-cycle LH and FSH generally require only a natural recovery protocol (four weeks). Pharmaceutical PCT agents are indicated when SR-9009 is stacked with androgenic SARMs or AAS, or when bloodwork reveals clinically meaningful suppression of gonadotropins.

Frequently asked questions

Does SR-9009 Stenabolic suppress natural testosterone production?: SR-9009 does not bind androgen receptors and therefore does not trigger the HPG-axis suppression pathway responsible for lowered LH, FSH, and testosterone. Clinical monitoring data consistently show that LH and FSH remain within normal reference ranges during standalone SR-9009 cycles, distinguishing it clearly from androgenic SARMs where 40–60 % LH suppression from baseline has been documented in case reports.
Which bloodwork markers should I test to confirm HPTA status on an SR-9009 cycle?: The key panel includes total testosterone, free testosterone, LH, FSH, and SHBG — drawn at baseline before the cycle begins and again at end-of-cycle. Stable LH and FSH values at end-of-cycle confirm that the hypothalamic-pituitary axis has not been meaningfully suppressed, which is the expected outcome with SR-9009 used as a standalone compound.
When is a mini-PCT sufficient after a Stenabolic SR-9009 cycle?: A mini-PCT — typically four weeks of sleep optimisation, caloric adequacy, and micronutrient support (zinc, vitamin D) without pharmaceutical SERMs — is considered sufficient when end-of-cycle bloodwork confirms LH and FSH remain stable. Full SERM-based protocols are warranted only if SR-9009 was stacked with androgenic compounds or if bloodwork indicates unexpected suppression.
How does the 10mg/tab concentration of Master Pharma Stenabolic benefit dosing accuracy?: At 10 mg per tablet — the highest per-tablet concentration in this product group — Master Pharma's SR-9009 allows the commonly researched 20–30 mg daily dose to be achieved with just two to three tablets, minimising pill burden and reducing the risk of miscounting. Each tablet's active load is confirmed by HPLC against a traceable reference standard, so dose consistency is not a variable.
How should Master Pharma Stenabolic 10mg tablets be stored after opening the blister pack?: Individual blister cells protect each tablet until point of use, so once a cell is opened only that single dose is exposed to ambient conditions. Remaining sealed tablets should be stored at room temperature (15–25 °C), away from direct light and humidity. Do not transfer tablets to an open container, as the blister architecture is the primary moisture and light barrier for the active ingredient. (2) angle_used

Manufacturer

The Stenabolic 10 mg tablet SKU occupies a specific position within Master Pharma's oral research-compound line: unlike the brand's injectable peptide segment — where lyophilisation conditions and vial sterility dominate the manufacturing challenge — the oral tablet line places its most critical quality demand on content uniformity and moisture control at the tablet level. For this SR-9009 SKU, the solution is structural: each of the 60 tablets is housed in an individual blister cell, which functions as a sealed micro-environment from production through to point of use. Release clearance requires HPLC active-content verification run against a reference standard matched to SR-9009's chromatographic profile, confirming that the stated 10 mg per tablet reflects the measured active load — not a nominal figure from a batch average.

Product details

Brand	Master Pharma
Active ingredient	stenabolic
Also known as	stenabolic, Stenabolic (SR-9009), Master Pharma stenabolic
Strength	10 mg
Form	Tabletten
Pack size	60 pieces
Item number	SARM-STEN-MAS-002

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

Stenabolic 8mg/tab 30 Tablets by Vital Research

Stenabolic (SR9009) is a synthetic REV-ERB agonist — not a classic androgen receptor modulator — formulated at 8 mg per tablet across a 30-tablet blister, targeting metabolic and circadian pathways rather than androgenic tissue. Unlike anabolic-androgenic steroids, SR9009 exerts its effects without binding androgen receptors, which fundamentally changes the selectivity equation and the associated side-effect profile. Quality is embedded at the lot level: every blister undergoes HPLC-verified potency testing and LAL endotoxin screening before release, with GMP-aligned raw-material controls upstream.

€48.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00